Ebola vaccine being used in Congo produces lasting antibody response, study finds
FINDINGSA new study by UCLA researchers and colleagues demonstrates that the Ebola vaccine known as rVSV ΔG-ZEBOV-GP results in a robust and enduring antibody response among vaccinated individuals in areas of the Democratic Republic of Congo that are experiencing outbreaks of the disease. Among the more than 600 study participants, 95.6% demonstrated antibody persistence six months after they received the vaccine.The study is the first published research examining post –Ebola-vaccination antibody response in the DRC, a nation of nearly 90 million. While long-term analyses of the study cohort continue, the findings will ...
Source: UCLA Newsroom: Health Sciences - February 8, 2022 Category: Universities & Medical Training Source Type: news
Fully Ready to Kill, Shockingly Unprepared to Save Lives
Credit: Albert Gonzalez Farran / UNAMIDBy Baher KamalMADRID, Jan 14 2022 (IPS) While absolutely ready to kill, with the biggest military powers spending in 2020 nearly two trillion US dollars on weapons, the world is shockingly unprepared to save the lives of millions of unarmed, innocent civilian victims of wars… and other man-made catastrophes.
The military spending data come from the Stockholm International Peace Research Institute (SIPRI), which also reports that global nuclear arsenals grow as states continue to modernise, thus sharply increasing the dangers of an unimaginable number of victims of the most devastati...
Source: IPS Inter Press Service - Health - January 14, 2022 Category: International Medicine & Public Health Authors: Baher Kamal Tags: Development & Aid Economy & Trade Global Global Governance Headlines Health Peace Poverty & SDGs TerraViva United Nations Source Type: news
Johnson & Johnson COVID-19 Vaccine Fully Approved by Health Canada to Prevent COVID-19 in Individuals 18 years and Older
Toronto ON, 24 November 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has approved its single-shot COVID-19 vaccine to prevent COVID-19 in individuals 18 years of age and older. This decision was based on scientific evidence, including initial data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease, and showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination. “We are delighted by Health Canada’s decision to approve the Johnson & Johnson COVID-...
Source: Johnson and Johnson - November 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Antimicrobial Resistance Calls for Brainpower of a Space Agency and Campaigning Zeal of an NGO
This article is republished from The Conversation under a Creative Commons license. Read the original article. (Source: IPS Inter Press Service - Health)
Source: IPS Inter Press Service - Health - November 17, 2021 Category: International Medicine & Public Health Authors: External Source Tags: Global Headlines Health Source Type: news
University of Oxford starts new Ebola vaccine trials
Clinical trials are under way for a new Ebola vaccine developed by the University of Oxford. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - November 11, 2021 Category: Consumer Health News Source Type: news
New Ebola vaccine made by team behind Oxford/AstraZeneca Covid vaccine starts human trials
The jab - currently known as ChAdOx1 biEBOV - uses the same technology as the breakthrough coronavirus shot. It has been designed to tackle the Zaire and Sudan strains of Ebola. (Source: the Mail online | Health)
Source: the Mail online | Health - November 11, 2021 Category: Consumer Health News Source Type: news
Human trials of vaccine for multiple species of Ebola to begin soon
It is hoped vaccine based on similar technology to Oxford Covid jab can protect against both Zaire and Sudan species of virusThe first jab of a new Ebola vaccine that may protect against multiple species of the virus is to be given on Thursday, researchers have said, with the vaccine based on similar technology to the Oxford Covid jab.Ebola haemorrhagic fever is caused by the Ebola virus and has caused devastation in some parts of the world. It is thought the outbreak inwest Africa in 2014-16 may have led to more than 11,000 deaths, while theoutbreak in the DRC between August 2018 and June 2020 claimedmore than 2,200 lives...
Source: Guardian Unlimited Science - November 11, 2021 Category: Science Authors: Nicola Davis Science correspondent Tags: Ebola Vaccines and immunisation UK news World news Medical research Health Society Source Type: news
Johnson & Johnson Enters into Agreement to Provide its Single-Shot COVID-19 Vaccine for the World ’s Most Vulnerable People through Novel Humanitarian Buffer
NEW BRUNSWICK, NJ (November 10, 2021) – Johnson & Johnson (NYSE: JNJ) (the Company) has entered into an agreement with the U.S. Government and Gavi, the Vaccine Alliance (Gavi), to enable access to its single-shot COVID-19 vaccine through a novel mechanism – the COVAX Humanitarian Buffer – that will serve to protect the world’s most vulnerable people. The first deliveries to the COVAX Humanitarian Buffer are anticipated to begin in the coming days.The COVAX Humanitarian Buffer is part of the COVAX Facility and is designed to ensure that people in conflict zones or humanitarian settings can access COVID-19 vacci...
Source: Johnson and Johnson - November 10, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Anne Rimoin named to new Gordon –Levin Chair in Infectious Diseases and Public Health
Anne Rimoin, an internationally recognized expert on emerging infections, global health, infectious disease surveillance systems and vaccinations who has been engaged in pandemic preparedness and response work for more than two decades, has been appointed to the newly established Gordon –Levin Endowed Chair in Infectious Diseases and Public Health at theUCLA Fielding School of Public Health.The chair was established by a $2 million gift from Tom and Edna Gordon and the Don S. Levin Trust to support the teaching and research activities of a faculty member with expertise in the epidemiology, transmission and control of inf...
Source: UCLA Newsroom: Health Sciences - November 9, 2021 Category: Universities & Medical Training Source Type: news
Statement on Data Published in PLOS Medicine on Tolerability and Immune Response of Johnson & Johnson Ebola Vaccine Regimen in Adults Living with HIV
NEW BRUNSWICK, N.J., October 29, 2021 – Data published in PLOS Medicine demonstrated that the Johnson & Johnson (the Company) Ebola vaccine regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo), was well tolerated and induced a robust immune response in both healthy adults and adults living with HIV. These findings, alongside Phase 3 data recently published in The Lancet Infectious Diseases, support the potential prophylactic use of the vaccine regimen to protect people at risk of acquiring Ebola. The regimen was granted Marketing Authorisation by the European Commission in July 2020 and Prequalification from th...
Source: Johnson and Johnson - October 29, 2021 Category: Pharmaceuticals Source Type: news
CDC: Advisory Committee on Immunization Practices (ACIP)
Notice that the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) is hosting a virtual meeting on November 2-3, 2021. The agenda will include discussions on adult immunization schedule, child/adolescent immunization schedule, Ebola vaccine, hepatitis vaccines, Orthopoxviruses vaccine, and COVID vaccines. Includes information on how to submit public comments or request permission to make a public comment during the meeting. Registration is not required, and the meeting is open to the public, available online via a live webcast. (Source: Federal Register updates via the Rural Assistance Center)
Source: Federal Register updates via the Rural Assistance Center - October 22, 2021 Category: Rural Health Source Type: news
Public Inspection: CDC: Meetings: Advisory Committee on Immunization Practices
Pre-publication notice that the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) is hosting a virtual meeting on November 2-3, 2021. The agenda will include discussions on adult immunization schedule, child/adolescent immunization schedule, Ebola vaccine, hepatitis vaccines, Orthopoxviruses vaccine, and COVID vaccines. Includes information on how to submit public comments or request permission to make a public comment during the meeting. Registration is not required, and the meeting is open to the public, available online via a live webcast. (Source: Federal Register upda...
Source: Federal Register updates via the Rural Assistance Center - October 21, 2021 Category: Rural Health Source Type: news
Congo-Kinshasa: Democratic Republic of the Congo Starts Ebola Vaccination
[WHO-AFRO] Brazzaville/Kinshasa -- Ebola vaccination began today in the Democratic Republic of the Congo's North Kivu Province where a case was confirmed on 8 October. People at high risk, including contacts of the confirmed case and first responders will receive the doses as the health authorities move to curb the spread of the virus. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - October 14, 2021 Category: African Health Source Type: news
Dr. Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson To Retire, Effective December 31, 2021
NEW BRUNSWICK, N.J. (October 12, 2021) – Johnson & Johnson (NYSE: JNJ) today announced that Paul Stoffels M.D., currently Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson, will retire from the Company effective December 31, 2021.As the Vice Chairman of the Executive Committee and Chief Scientific Officer, Dr. Stoffels spearheaded the company’s research and product pipeline leading teams across sectors to set the company-wide mandate to discover and develop transformational healthcare solutions. Under his leadership, Johnson & Johnson revitalized its innovation pipel...
Source: Johnson and Johnson - October 12, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
The World ’s First Malaria Vaccine—and What it Means for the Future of Pandemic Response
On Oct. 6, the World Health Organization recommended use of the first vaccine to fight malaria. The decision is momentous and highly anticipated for many reasons: among them is that this is the first vaccine to help reduce the risk of deadly severe malaria in young children in Sub-Saharan Africa, where the disease remains a leading killer.
The vaccine offers hope that there can be a circle of learning from one pandemic to the next. Malaria, our oldest pandemic, may offer insights on how we can survive contemporary scourges like COVID-19. Malaria evolved at least 2.5 million years ago and first infected humans in rural part...
Source: TIME: Health - October 7, 2021 Category: Consumer Health News Authors: Raj Panjabi Tags: Uncategorized health healthscienceclimate Source Type: news
